Benitec Biopharma last week said that it has completed its acquisition of Tacere Therapeutics, which was first announced last month.
As reported by Gene Silencing News, Benitec acquired Tacere and its preclinical hepatitis C program for just under $1.5 million in stock (GSN 10/11/2012).